Search

Your search keyword '"Nash, Danielle M"' showing total 90 results
Start Over Author "Nash, Danielle M"
90 results on '"Nash, Danielle M"'

55. Erratum : Grams ME, Sang Y, Ballew SH, et al, for the Chronic Kidney Disease Prognosis Consortium. Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. Kidney Int. 2018;93:1442–1451 (Kidney International (2018) 93(6) (1442–1451), (S0085253818300978) (10.1016/j.kint.2018.01.009))

Author

Astor, Brad, Appel, Lawrence J., Levin, Adeera, Tang, Mila, Djurdjev, Ognjenka, Navaneethan, Sankar D., Jolly, Stacey E., Schold, Jesse D., Nally, Joseph V., Wheeler, David C., Emberson, Jonathan, Townend, John, Landray, Martin, Feldman, Harold I., Hsu, Chi yuan, Lash, James P., Kalra, Philip A., Ritchie, James P., Maharajan, Raman, Middleton, Rachel J., O'Donoghue, Donal J., Eckardt, Kai Uwe, Schneider, Markus P., Köttgen, Anna, Kronenberg, Florian, Bärthlein, Barbara, Chang, Alex R., Green, Jamie A., Kirchner, H. Lester, Ho, Kevin, Marks, Angharad, Black, Corri, Prescott, Gordon J., Fluck, Nick, Nakayama, Masaaki, Miyazaki, Mariko, Yamamoto, Tae, Yamada, Gen, Wang, Angela Yee Moon, Cheung, Sharon, Wong, Sharon, Chu, Jessie, Wu, Henry, Garg, Amit X., McArthur, Eric, Nash, Danielle M., Blankestijn, Peter J., van Zuilen, Arjan D., Visseren, Frank L.J., and van der Graaf, Yolanda

Subjects
Nephrology
Abstract

The Chronic Kidney Disease (CKD) Prognosis Consortium is a collaborative author of the above-mentioned article. The CKD Prognosis Consortium investigators/collaborators are as follows: • African American Study of Kidney Disease and Hypertension (AASK): Brad Astor, Lawrence J. Appel; Canadian Study of Prediction of Death, Dialysis and Interim Cardiovascular Events (CanPREDDICT): Adeera Levin, Mila Tang, Ognjenka Djurdjev; Cleveland Clinic CKD Registry Study (CCF): Sankar D. Navaneethan, Stacey E. Jolly, Jesse D. Schold, Joseph V. Nally Jr.; Chronic Renal Impairment in Birmingham (CRIB): David C. Wheeler, Jonathan Emberson, John Townend, Martin Landray; Chronic Renal Insufficiency Cohort Study (CRIC): Harold I. Feldman, Chi-yuan Hsu, James P. Lash, Lawrence J. Appel; Chronic Renal Insufficiency Standards Implementation Study (CRISIS): Philip A. Kalra, James P. Ritchie, Raman Maharajan, Rachel J. Middleton, Donal J. O'Donoghue; German Chronic Kidney Disease Study (GCKD): Kai-Uwe Eckardt, Markus P. Schneider, Anna Köttgen, Florian Kronenberg, Barbara Bärthlein; Geisinger Health System: Alex R. Chang, Jamie A. Green, H. Lester Kirchner, Kevin Ho; Grampian Laboratory Outcomes, Morbidity and Mortality Studies – 2 (GLOMMS2): Angharad Marks, Corri Black, Gordon J. Prescott, Nick Fluck; Gonryo Study: Masaaki Nakayama, Mariko Miyazaki, Tae Yamamoto, Gen Yamada; Hong Kong CKD Studies: Angela Yee-Moon Wang, Sharon Cheung, Sharon Wong, Jessie Chu, Henry Wu; Ontario Institute for Clinical Evaluative Sciences, Provincial Kidney, Dialysis and Transplantation program (ICES KDT): Amit X. Garg, Eric McArthur, Danielle M. Nash; Maccabi Health System: Varda Shalev, Gabriel Chodick; Multifactorial Approach and Superior Treatment Efficacy in Renal Patients with the Aid of a Nurse Practitioner (MASTERPLAN): Peter J. Blankestijn, Jack F.M. Wetzels, Arjan D. van Zuilen, Jan A. van den Brand; Modification of Diet in Renal Disease Study (MDRD): Andrew S. Levey, Lesley A. Inker, Mark J. Sarnak, Hocine Tighiouart; Nanjing CKD Network Cohort Study (Nanjing CKD): Haitao Zhang; NephroTest Study (NephroTest): Benedicte Stengel, Marie Metzger, Martin Flamant, Pascal Houillier, Jean-Philippe Haymann; National Renal Healthcare Program – Uruguay (NRHP-URU): Pablo G. Rios, Nelson Mazzuchi, Liliana Gadola, Verónica Lamadrid, Laura Sola; New Zealand Diabetes Cohort Study (NZDCS): John F. Collins, C. Raina Elley, Timothy Kenealy; Parcours de Soins des Personnes Agées (PSPA): Olivier Moranne, Cecile Couchoud, Cecile Vigneau; Primary-Secondary Care Partnership to Prevent Adverse Outcomes in Chronic Kidney Disease (PSP CKD): Nigel J. Brunskill, Rupert W. Major, David Shepherd, James F. Medcalf; Racial and Cardiovascular Risk Anomalies in CKD Cohort (RCAV): Csaba P. Kovesdy, Kamyar Kalantar-Zadeh, Miklos Z. Molnar, Keiichi Sumida, Praveen K. Potukuchi; Reduction of Endpoints in Non-insulin Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL): Hiddo J.L. Heerspink, Dick de Zeeuw, Barry Brenner; Stockholm CREAtinine Measurements Cohort (SCREAM): Juan Jesus Carrero, Alessandro Gasparini, Abdul Rashid Qureshi, Carl-Gustaf Elinder; Second Manifestations of ARTerial Disease Study (SMART): Frank L.J. Visseren, Yolanda van der Graaf; Swedish Renal Registry CKD Cohort (SRR CKD): Marie Evans, Maria Stendahl, Staffan Schön, Mårten Segelmark, Karl-Göran Prütz; Sunnybrook Cohort: David M. Naimark, Navdeep Tangri; West of Scotland CKD Study: Patrick B. Mark, Jamie P. Traynor, Colin C. Geddes, Peter C. Thomson.• CKD Prognosis Consortium Steering Committee: Alex R. Chang, Josef Coresh (Chair), Ron T. Gansevoort, Morgan E. Grams, Anna Köttgen, Andrew S. Levey, Kunihiro Matsushita, Mark Woodward, Luxia Zhang.• CKD Prognosis Consortium Data Coordinating Center: Shoshana H. Ballew (Assistant Project Director), Jingsha Chen (Programmer), Josef Coresh (Principal Investigator), Morgan E. Grams (Director of Nephrology Initiatives), Lucia Kwak (Programmer), Kunihiro Matsushita (Director), Yingying Sang (Lead Programmer), Aditya Surapaneni (Programmer), Mark Woodward (Senior Statistician).• Kidney Disease Improving Global Outcomes (KDIGO) Controversies Conference on Prognosis and Optimal Management of Patients with Advanced CKD: Kai-Uwe Eckardt (Conference Co-Chair), Brenda R. Hemmelgarn (Conference Co-Chair), David C. Wheeler (KDIGO Co-Chair), Wolfgang C. Winkelmayer (KDIGO Co-Chair), John Davis (CEO), Danielle Green (Managing Director), Michael Cheung (Chief Scientific Officer), Tanya Green (Communications Director), Melissa McMahan (Programs Director).

Published
2018

56. Supplementary_Tables – Supplemental material for Validity of administrative database code algorithms to identify vascular access placement, surgical revisions, and secondary patency

Author

Al-Jaishi, Ahmed A, Moist, Louise M, Oliver, Matthew J, Nash, Danielle M, Fleet, Jamie L, Garg, Amit X, and Lok, Charmaine E

Subjects
Cardiology
Abstract

Supplemental material, Supplementary_Tables for Validity of administrative database code algorithms to identify vascular access placement, surgical revisions, and secondary patency by Ahmed A Al-Jaishi, Louise M Moist, Matthew J Oliver, Danielle M Nash, Jamie L Fleet, Amit X Garg and Charmaine E Lok in The Journal of Vascular Access

Published
2018
Full Text
View/download PDF

59. Acute Kidney Injury in Patients Receiving Systemic Treatment for Cancer: A Population-Based Cohort Study

Author

Kitchlu, Abhijat, primary, McArthur, Eric, additional, Amir, Eitan, additional, Booth, Christopher M, additional, Sutradhar, Rinku, additional, Majeed, Habeeb, additional, Nash, Danielle M, additional, Silver, Samuel A, additional, Garg, Amit X, additional, Chan, Christopher T, additional, Kim, S Joseph, additional, and Wald, Ron, additional

Published
2018
Full Text
View/download PDF

60. Diagnostic accuracy of administrative codes for autosomal dominant polycystic kidney disease in clinic patients with cystic kidney disease.

Author

Kalatharan, Vinusha, McArthur, Eric, Nash, Danielle M, Welk, Blayne, Sarma, Sisira, Garg, Amit X, and Pei, York

Subjects
POLYCYSTIC kidney disease, CYSTIC kidney disease, INTERNATIONAL Statistical Classification of Diseases & Related Health Problems, NOSOLOGY
Abstract

Background The ability to identify patients with autosomal dominant polycystic kidney disease (ADPKD) and distinguish them from patients with similar conditions in healthcare administrative databases is uncertain. We aimed to measure the sensitivity and specificity of different ADPKD administrative coding algorithms in a clinic population with non-ADPKD and ADPKD kidney cystic disease. Methods We used a dataset of all patients who attended a hereditary kidney disease clinic in Toronto, Ontario, Canada between 1 January 2010 and 23 December 2014. This dataset included patients who met our reference standard definition of ADPKD or other cystic kidney disease. We linked this dataset to healthcare databases in Ontario. We developed eight algorithms to identify ADPKD using the International Classification of Diseases, 10th Revision (ICD-10) codes and provincial diagnostic billing codes. A patient was considered algorithm positive if any one of the codes in the algorithm appeared at least once between 1 April 2002 and 31 March 2015. Results The ICD-10 coding algorithm had a sensitivity of 33.7% [95% confidence interval (CI) 30.0–37.7] and a specificity of 86.2% (95% CI 75.7–92.5) for the identification of ADPKD. The provincial diagnostic billing code had a sensitivity of 91.1% (95% CI 88.5–93.1) and a specificity of 10.8% (95% CI 5.3–20.6). Conclusions ICD-10 coding may be useful to identify patients with a high chance of having ADPKD but fail to identify many patients with ADPKD. Provincial diagnosis billing codes identified most patients with ADPKD and also with other types of cystic kidney disease. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

61. Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate

Author

Grams, Morgan E., primary, Sang, Yingying, additional, Ballew, Shoshana H., additional, Carrero, Juan Jesus, additional, Djurdjev, Ognjenka, additional, Heerspink, Hiddo J.L., additional, Ho, Kevin, additional, Ito, Sadayoshi, additional, Marks, Angharad, additional, Naimark, David, additional, Nash, Danielle M., additional, Navaneethan, Sankar D., additional, Sarnak, Mark, additional, Stengel, Benedicte, additional, Visseren, Frank L.J., additional, Wang, Angela Yee-Moon, additional, Köttgen, Anna, additional, Levey, Andrew S., additional, Woodward, Mark, additional, Eckardt, Kai-Uwe, additional, Hemmelgarn, Brenda, additional, and Coresh, Josef, additional

Published
2018
Full Text
View/download PDF

65. Causes of Death after a Hospitalization with AKI

Author

Silver, Samuel A., primary, Harel, Ziv, additional, McArthur, Eric, additional, Nash, Danielle M., additional, Acedillo, Rey, additional, Kitchlu, Abhijat, additional, Garg, Amit X., additional, Chertow, Glenn M., additional, Bell, Chaim M., additional, and Wald, Ron, additional

Published
2017
Full Text
View/download PDF

71. Acute Kidney Injury in Patients Receiving Systemic Treatment for Cancer: A Population-Based Cohort Study.

Author

Kitchlu, Abhijat, McArthur, Eric, Amir, Eitan, Booth, Christopher M, Sutradhar, Rinku, Majeed, Habeeb, Nash, Danielle M, Silver, Samuel A, Garg, Amit X, Chan, Christopher T, Kim, S Joseph, and Wald, Ron

Subjects
KIDNEY injuries, CANCER treatment, ACE inhibitors, THERAPEUTICS, ANGIOTENSIN receptors, KIDNEY diseases
Abstract

Background: Patients undergoing treatment for cancer are at increased risk of acute kidney injury (AKI). There are few data on AKI incidence and risk factors in the current era of cancer treatment.Methods: We conducted a population-based study of all patients initiating systemic therapy (chemotherapy or targeted agents) for a new cancer diagnosis in Ontario, Canada (2007-2014). The primary outcome was hospitalization with AKI or acute dialysis. We estimated the cumulative incidence of AKI and fitted Fine and Gray models, adjusting for demographics, cancer characteristics, comorbidities, and coprescriptions. We modeled exposure to systemic therapy (the 90-day period following treatments) as a time-varying covariate. We also assessed temporal trends in annual AKI incidence.Results: We identified 163 071 patients initiating systemic therapy of whom 10 880 experienced AKI. The rate of AKI was 27 per 1000 person-years, with overall cumulative incidence of 9.3% (95% CI = 9.1% to 9.6%). Malignancies with the highest 5-year AKI incidence were myeloma (26.0%, 95% CI = 24.4% to 27.7%), bladder (19.0%, 95% CI = 17.6% to 20.5%), and leukemia (15.4%, 95% CI = 14.3% to 16.5%). Advanced cancer stage, chronic kidney disease, and diabetes were associated with increased risk of AKI (adjusted hazard ratios [aHR] = 1.41, 95% CI = 1.28 to 1.54; 1.80, 95% CI = 1.67 to 1.93; and 1.43, 95% CI = 1.37 to 1.50, respectively). In patients aged 66 years or older with universal drug benefits, diuretic, and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker coprescription was associated with higher AKI risk (aHR = 1.20, 95% CI = 1.14 to 1.28; 1.30, 95% CI = 1.23 to 1.38). AKI risk was further accentuated during the 90-day period following systemic therapy (aHR = 2.34, 95% CI = 2.24 to 2.45). The annual incidence of AKI increased from 18 to 52 per 1000 person-years between 2007 and 2014.Conclusion: Cancer-related AKI is common and associated with advanced stage, chronic kidney disease, diabetes, and concomitant receipt of diuretics or angiotensin-converting enzyme inhibitors/angiotensin receptor blockers. Risk is heightened in the 90 days after systemic therapy. Preventive strategies are needed to address the increasing burden of AKI in this population. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

72. Nephrology comanagement and the quality of antibiotic prescribing in primary care for patients with chronic kidney disease: a retrospective cross-sectional study.

Author

Zhu, Justin X G, Nash, Danielle M, McArthur, Eric, Farag, Alexandra, Garg, Amit X, and Jain, Arsh K

Subjects
*PRIMARY care, *CHRONICALLY ill, *CROSS-sectional method, *GLOMERULAR filtration rate, *NEPHROLOGY
Abstract

Background In primary care, patients with chronic kidney disease (CKD) are frequently prescribed excessive doses of antibiotics relative to their kidney function. We examined whether nephrology comanagement is associated with improved prescribing in primary care. Methods In a retrospective propensity score–matched cross-sectional study, we studied the appropriateness of antibiotic prescriptions by primary care physicians to Ontarians ≥66 years of age with CKD Stages 4 and 5 (estimated glomerular filtration rate <30 mL/min/1.73 m2 not receiving dialysis) from 1 April 2003 to 31 March 2014. Comanagement was defined as having at least one outpatient visit with a nephrologist within the year prior to antibiotic prescription date. We compared the rate of appropriately dosed antibiotics in primary care between 3937 patients who were comanaged by a nephrologist and 3937 patients who were not. Results Only 1184 (30%) of 3937 noncomanaged patients had appropriately dosed antibiotic prescriptions prescribed by a primary care physician. Nephrology comanagement was associated with an increased likelihood that an appropriately dosed prescription was prescribed by a primary care physician; however, the magnitude of the effect was modest [1342/3937 (34%); odds ratio 1.20 (95% confidence interval 1.09–1.32); P < 0.001]. Conclusion The majority of antibiotics prescribed by primary care physicians are inappropriately dosed in CKD patients, whether or not a nephrologist is comanaging the patient. Nephrologists have an opportunity to increase awareness of appropriate dosing of medications in primary care through the patients they comanage. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

76. Positive Predictive Values of International Classification of Diseases, 10th Revision Coding Algorithms to Identify Patients With Autosomal Dominant Polycystic Kidney Disease

Author

Kalatharan, Vinusha, primary, Pei, York, additional, Clemens, Kristin K., additional, McTavish, Rebecca K., additional, Dixon, Stephanie N., additional, Rochon, Matthew, additional, Nash, Danielle M., additional, Jain, Arsh, additional, Sarma, Sisira, additional, Zaleski, Andrew, additional, Lum, Andrea, additional, and Garg, Amit X., additional

Published
2016
Full Text
View/download PDF

77. Rehospitalizations and Emergency Department Visits after Hospital Discharge in Patients Receiving Maintenance Hemodialysis

Author

Harel, Ziv, primary, Wald, Ron, additional, McArthur, Eric, additional, Chertow, Glenn M., additional, Harel, Shai, additional, Gruneir, Andrea, additional, Fischer, Hadas D., additional, Garg, Amit X., additional, Perl, Jeffrey, additional, Nash, Danielle M., additional, Silver, Samuel, additional, and Bell, Chaim M., additional

Published
2015
Full Text
View/download PDF

82. sj-pdf-1-cjk-10.1177_2054358120972830 – Supplemental material for Complications in Patients With Autosomal Dominant Polycystic Kidney Disease Undergoing Ureteroscopy: A Cohort Study

Author

Vinusha Kalatharan, Welk, Blayne, Nash, Danielle M., McArthur, Eric, Slater, Justin, Sarma, Sisira, Pei, York, and Garg, Amit X.

Subjects
Medicine, 3. Good health
Abstract

Supplemental material, sj-pdf-1-cjk-10.1177_2054358120972830 for Complications in Patients With Autosomal Dominant Polycystic Kidney Disease Undergoing Ureteroscopy: A Cohort Study by Vinusha Kalatharan, Blayne Welk, Danielle M. Nash, Eric McArthur, Justin Slater, Sisira Sarma, York Pei and Amit X. Garg in Canadian Journal of Kidney Health and Disease

83. SUPPLEMENTARY_MATERIALS_1 – Supplemental material for Efficacy and Safety of Surgical Kidney Stone Interventions in Autosomal Dominant Polycystic Kidney Disease: A Systematic Review

Author

Vinusha Kalatharan, Jandoc, Racquel, Grewal, Gary, Nash, Danielle M., Welk, Blayne, Sarma, Sisira, Pei, York, and Garg, Amit X.

Subjects
urogenital system, Medicine, 3. Good health
Abstract

Supplemental material, SUPPLEMENTARY_MATERIALS_1 for Efficacy and Safety of Surgical Kidney Stone Interventions in Autosomal Dominant Polycystic Kidney Disease: A Systematic Review by Vinusha Kalatharan, Racquel Jandoc, Gary Grewal, Danielle M. Nash, Blayne Welk, Sisira Sarma, York Pei and Amit X. Garg in Canadian Journal of Kidney Health and Disease

84. SUPPLEMENTARY_MATERIALS_1 – Supplemental material for Efficacy and Safety of Surgical Kidney Stone Interventions in Autosomal Dominant Polycystic Kidney Disease: A Systematic Review

Author

Vinusha Kalatharan, Jandoc, Racquel, Grewal, Gary, Nash, Danielle M., Welk, Blayne, Sarma, Sisira, Pei, York, and Garg, Amit X.

Subjects
urogenital system, Medicine, 3. Good health
Abstract

Supplemental material, SUPPLEMENTARY_MATERIALS_1 for Efficacy and Safety of Surgical Kidney Stone Interventions in Autosomal Dominant Polycystic Kidney Disease: A Systematic Review by Vinusha Kalatharan, Racquel Jandoc, Gary Grewal, Danielle M. Nash, Blayne Welk, Sisira Sarma, York Pei and Amit X. Garg in Canadian Journal of Kidney Health and Disease

85. sj-pdf-1-cjk-10.1177_20543581211000227 – Supplemental material for Risk of Hospital Encounters With Kidney Stones in Autosomal Dominant Polycystic Kidney Disease: A Cohort Study

Author

Vinusha Kalatharan, Welk, Blayne, Nash, Danielle M., Dixon, Stephanie N., Slater, Justin, Pei, York, Sarma, Sisira, and Garg, Amit X.

Subjects
Medicine, 3. Good health
Abstract

Supplemental material, sj-pdf-1-cjk-10.1177_20543581211000227 for Risk of Hospital Encounters With Kidney Stones in Autosomal Dominant Polycystic Kidney Disease: A Cohort Study by Vinusha Kalatharan, Blayne Welk, Danielle M. Nash, Stephanie N. Dixon, Justin Slater, York Pei, Sisira Sarma and Amit X. Garg in Canadian Journal of Kidney Health and Disease

86. SupplementaryMaterials_PrevalenceOfStone_CJKHD – Supplemental material for Stone Prevalence in Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Meta-Analysis

Author

Vinusha Kalatharan, Grewal, Gary, Nash, Danielle M, Welk, Blayne, Sarma, Sisira, Pei, York, and Garg, Amit X.

Subjects
Medicine, 3. Good health
Abstract

Supplemental material, SupplementaryMaterials_PrevalenceOfStone_CJKHD for Stone Prevalence in Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Meta-Analysis by Vinusha Kalatharan, Gary Grewal, Danielle M Nash, Blayne Welk, Sisira Sarma, York Pei and Amit X. Garg in Canadian Journal of Kidney Health and Disease

87. sj-pdf-1-cjk-10.1177_20543581211000227 – Supplemental material for Risk of Hospital Encounters With Kidney Stones in Autosomal Dominant Polycystic Kidney Disease: A Cohort Study

Author

Vinusha Kalatharan, Welk, Blayne, Nash, Danielle M., Dixon, Stephanie N., Slater, Justin, Pei, York, Sarma, Sisira, and Garg, Amit X.

Subjects
Medicine, 3. Good health
Abstract

Supplemental material, sj-pdf-1-cjk-10.1177_20543581211000227 for Risk of Hospital Encounters With Kidney Stones in Autosomal Dominant Polycystic Kidney Disease: A Cohort Study by Vinusha Kalatharan, Blayne Welk, Danielle M. Nash, Stephanie N. Dixon, Justin Slater, York Pei, Sisira Sarma and Amit X. Garg in Canadian Journal of Kidney Health and Disease

88. sj-pdf-1-cjk-10.1177_2054358120972830 – Supplemental material for Complications in Patients With Autosomal Dominant Polycystic Kidney Disease Undergoing Ureteroscopy: A Cohort Study

Author

Vinusha Kalatharan, Welk, Blayne, Nash, Danielle M., McArthur, Eric, Slater, Justin, Sarma, Sisira, Pei, York, and Garg, Amit X.

Subjects
Medicine, 3. Good health
Abstract

Supplemental material, sj-pdf-1-cjk-10.1177_2054358120972830 for Complications in Patients With Autosomal Dominant Polycystic Kidney Disease Undergoing Ureteroscopy: A Cohort Study by Vinusha Kalatharan, Blayne Welk, Danielle M. Nash, Eric McArthur, Justin Slater, Sisira Sarma, York Pei and Amit X. Garg in Canadian Journal of Kidney Health and Disease

89. SupplementaryMaterials_PrevalenceOfStone_CJKHD – Supplemental material for Stone Prevalence in Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Meta-Analysis

Author

Vinusha Kalatharan, Grewal, Gary, Nash, Danielle M, Welk, Blayne, Sarma, Sisira, Pei, York, and Garg, Amit X.

Subjects
Medicine, 3. Good health
Abstract

Supplemental material, SupplementaryMaterials_PrevalenceOfStone_CJKHD for Stone Prevalence in Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Meta-Analysis by Vinusha Kalatharan, Gary Grewal, Danielle M Nash, Blayne Welk, Sisira Sarma, York Pei and Amit X. Garg in Canadian Journal of Kidney Health and Disease

90. Long-Term Kidney Outcomes after Pediatric Acute Kidney Injury.

Author

Robinson CH, Jeyakumar N, Luo B, Askenazi D, Deep A, Garg AX, Goldstein S, Greenberg JH, Mammen C, Nash DM, Parekh RS, Silver SA, Thabane L, Wald R, Zappitelli M, and Chanchlani R

Abstract

Background: Acute kidney injury (AKI) is common in hospitalized children. Pediatric AKI receiving acute kidney replacement therapy (KRT) is associated with long-term chronic kidney disease (CKD), hypertension, and death. We aim to determine the outcomes after AKI in children who did not receive acute KRT, since these remain uncertain., Methods: Retrospective cohort study of all hospitalized children (0-18 years) surviving AKI without acute KRT between 1996-2020 in Ontario, Canada, identified by validated diagnostic codes in provincial administrative health databases. Children with prior KRT, CKD, or AKI were excluded. Cases were matched with up to four hospitalized comparators without AKI by age, neonatal status, sex, intensive care unit admission, cardiac surgery, malignancy, hypertension, hospitalization era, and a propensity score for AKI. Patients were followed until death, provincial emigration, or censoring in March 2021. The primary outcome was long-term major adverse kidney events (MAKE-LT; a composite of all-cause mortality, long-term KRT, or incident CKD)., Results: We matched 4,173 pediatric AKI survivors with 16,337 hospitalized comparators. Baseline covariates were well-balanced following propensity score matching. During median 9.7-year follow-up, 18% of AKI survivors developed MAKE-LT vs. 5% of hospitalized comparators (hazard ratio [HR] 4.0, 95% confidence interval [CI] 3.6-4.4). AKI survivors had higher rates of long-term KRT (2% vs. <1%; HR 11.7, 95%CI 7.5-18.4), incident CKD (16% vs. 2%; HR 7.9, 95%CI 6.9-9.1), incident hypertension (17% vs. 8%; HR 2.3, 95%CI 2.1-2.6), and AKI during subsequent hospitalization (6% vs. 2%; HR 3.7, 95%CI 3.1-4.5), but no difference in all-cause mortality (3% vs. 3%; HR 0.9, 95%CI 0.7-1.1)., Conclusions: Children surviving AKI without acute KRT were at higher long-term risk of CKD, long-term KRT, hypertension, and subsequent AKI vs. hospitalized comparators., (Copyright © 2024 by the American Society of Nephrology.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results